Your cart: Items:, Value:
 

Contra-indications/Dosage/Warnings

Equest Worming Gel

Horses must not be slaughtered for human consumption within 32 days of treatment.

Do not administer to young foals less than 4 months of age.

EQUEST Oral Gel is formulated specifically for use in horses only. Dogs or cats may be adversely affected by the concentration of moxidectin in this product if they are allowed to ingest spilled gel or have access to used syringes.

Do not administer in case of known hypersensitivity to the active ingredient or to any other milbemycins and to any other ingredients of the veterinary medicinal product.

Do not use the same syringe to treat more than one animal unless horses are running together or in direct contact with each other on the same premises.

Do not smoke, drink or eat while handling the product.

The use of protective gloves is recommended.

Wash hands or any exposed area after use.

Avoid direct contact with skin and eyes.

In the event of eye contact, flush the eye with copious amounts of clean water and seek medical advice.

For animal treatment only.

Keep out of reach of children.

Read entire package insert before use.

Environmental safety

EQUEST Oral Gel is toxic to fish and aquatic organisms. Do not contaminate ponds, waterways or ditches with product or used syringes. Dispose of any unused product and empty syringes in accordance with guidance from your local waste regulation authority

Presentation

A clear gel containing 18.92 mg/g moxidectin and 37.84 mg/g benzyl alcohol and 0.24 mg/g disodium edetate as preservatives.

Uses

Moxidectin is a second generation macrocyclic lactone of the milbemycin family.

For the treatment and control of adult and larval stages of important internal parasites including encysted inhibited EL3 and developing intramucosal L4 larval stages of small redworms, arterial stages of large redworms and bots in horses and ponies with a single dose.

EQUEST Oral Gel, at the recommended dosage level of 400 mcg moxidectin per kg bodyweight, provides effective control of moxidectin sensitive strains of the following parasites of horses and ponies:

Large strongyles:

Strongylus vulgaris (adults and arterial stages)

Strongylus edentatus (adults and visceral stages)

Triodontophorus brevicauda (adults)

Triodontophorus serratus (adults)

Triodontophorus tenuicollis (adults)

Small strongyles (adults and intraluminal larval stages):

Cyathostomum spp.

Cylicocyclus spp.

Cylicostephanus spp.

Cylicodontophorus spp.

Gyalocephalus spp.

EQUEST Oral Gel is effective against (developing) intramucosal L4 stages of small strongyles. At eight weeks after treatment early (hypobiotic) EL3 stages of small strongyles are eliminated.

EQUEST Oral Gel is effective against benzimidazole resistant strains of cyathostomes.

Ascarids:

Parascaris equorum (adult and larval stages)

Other species:

Oxyuris equi (adult and larval stages)

Habronema muscae (adults)

Gasterophilus intestinalis (L2, L3)

Gasterophilus nasalis (L2, L3)

Strongyloides westeri (adults)

Trichostrongylus axei

EQUEST Oral Gel has a persistent effect in preventing infection by small strongyles for 2 weeks after dosing and suppresses the presence of small strongyle eggs in the dung for 90 days.

Dosage and administration

For oral administration. One 12.2g syringe contains sufficient gel to treat one 575 kg horse at the recommended dose rate (0.4 mg moxidectin per kg bodyweight). Each graduation on the calibrated syringe delivers sufficient gel to treat 25 kg bodyweight. Use of a scale or weigh tape is recommended to ensure accurate dosing. To avoid overdosing, care should be taken to accurately dose foals, especially low bodyweight foals or young ponies.

Dosing guideline

The persistent activity of EQUEST Oral Gel and its effectiveness against inhibited and developing larvae in the intestinal mucosa enables a reduction in the dosing frequency in strategic parasite control programmes. The recommended dosing interval for the control of small strongyles is 13 weeks. Consult your veterinary surgeon for the appropriate programme for your specific needs

Pharmaceutical precautions

After opening, use within 6 months.

Do not store above 25°C.

Keep the syringe in the carton.

After first use record the date to be disposed on the label space provided.

Further information

EQUEST Oral Gel is safe to use in foals over 4 months of age, mares, ponies and horses. Mares may be treated at any stage of pregnancy and lactation. Transient adverse reactions may occur at twice the recommended dose in foals and 3 times the recommended dose in adults. The signs are depression, inappetence, ataxia and drooping lower lip 8 to 24 hours following dosing. Symptoms of moxidectin overdose are the same as those observed in very rare occasions at the recommended dosage. In addition, hypothermia may occur. Symptomatic treatment is not generally necessary and recovery is generally complete within 24 to 72 hours. There is no specific antidote.

EQUEST Oral Gel is specially formulated to be easily expelled by the syringe plunger. Once in the horse`s mouth, EQUEST Gel liquefies. This facilitates dosing and reduces the risk of rejection.

Eraquell Worming Paste

For animal treatment only.

Not to be used in mares producing milk for human consumption.

Some horses carrying heavy infection of Onchocerca microfilariae have experienced reactions with swelling and itching after treatment. It is assumed to be the result of death of large numbers of microfilariae.

These signs resolve within a few days but symptomatic treatment may be advisable.

Eraquell has been formulated specifically for use in horses. Dogs and cats may be adversely affected by the concentration of ivermectin in this product, if they are allowed to ingest spilled paste or have access to used syringes.

As ivermectin is extremely dangerous to fish and aquatic life, treated animals should not have direct access to surface water and ditches during treatment.

Wash hands after use.

Avoid eye contact.

Do not smoke or eat while handling the product.

Withdrawal period:

Horses may be slaughtered for human consumption only after 30 days from the last treatment.

Container disposal:

Any unused product or waste material should be disposed of in accordance with local requirements. Ivermectin is EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate surface water or ditches with the product or used containers.

Presentation

A white homogenous paste containing 1.87% w/w ivermectin Ph.Eur.

Uses

For the treatment and control of adult and immature gastrointestinal roundworms, lungworms and bots of horses, including:

Large strongyles

Strongylus vulgaris adults and 4th larval (arterial) stages

Strongylus edentatus adults and 4th larval (tissue) stages

Strongylus equinus adults

Small strongyles, adults

Cyathostomum spp.

Cylicocyclus spp.

Cylicodontophorus spp.

Cylicostephanus spp.

Gyalocephalus spp.

Hairworms

Trichostrongylus axei adults

Pinworms

Oxyuris equi adults and immatures

Ascarids

Parascaris equorum adults

Intestinal threadworms

Strongyloides westeri adults

Large-mouth stomach worms

Habronema muscae adults

Neck threadworms

Onchocerca spp. (microfilariae)

Lungworms

Dictyocaulus arnfieldi adult and immature

Stomach bots

Gasterophilus spp. oral and gastric larval stages

Dosage and administration

ERAQUELL paste is given by mouth at the recommended dose rate of 200 micrograms per kg of bodyweight as a single dose. Each syringe division delivers sufficient paste to treat 100kg of bodyweight (corresponding to 1.07g product and 20mg ivermectin). Each syringe delivers 140mg ivermectin, sufficient to treat 700kg of bodyweight.

The horse’s weight should be accurately determined to ensure use of the correct dose of product.

The animal’s mouth must be free of food. The syringe should be placed between the front and back teeth and the paste deposited at the base of the tongue. Immediately elevate the head for a few seconds to ensure that the product is swallowed. Re-treatment should be carried out according to the epidemiological situation and at not less than 30 day intervals. Eraquell may be used in pregnant mares.

Pharmaceutical precautions

Keep out of the reach of children. Store below 30° C.

Further information

No known interaction with other equine medicaments.

Eqvalan Worming Paste

Some horses carrying heavy infection of Onchocerca microfilariae have experienced oedema and pruritus following dosing, assumed to be the result of death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable.

EQVALAN Paste for Horses has been formulated specifically for use in horses and donkeys only. Dogs or cats may be adversely affected by the concentration of ivermectin in this product if they are allowed to ingest spilled paste or have access to used syringes.

Do not smoke, eat or drink while handling the product.

Wash hands after use.

This product may cause skin and eye irritation. Therefore, the user should avoid contact of the product with the skin and the eyes. In the case of contact rinse immediately with plenty of water.

In the case of accidental ingestion or eye irritation after contact seek medical advise immediately and show the package insert or the label to the physician.

For animal treatment only.

Withdrawal periods:

Donkeys - meat: 21 days.

Horses - meat: 21 days.

Container disposal:

EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate ponds, waterways or ditches with the product or used container. Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Presentation

A white ready-to-use paste formulation for oral administration containing 1.87% w/w ivermectin.

Uses

For the treatment and control of adult and immature roundworms, lungworms and bots of horses and donkeys.

EQVALAN Paste for Horses at the recommended dose rate of 200 micrograms ivermectin per kg bodyweight provides effective treatment and control of the following parasites of horses and donkeys:

Large strongyles

Strongylus vulgaris (adults and arterial larval stages), S. edentatus (adults and tissue larval stages), S. equinus (adults), Triodontophorus spp. (adults), T. brevicauda, T. serratus, Craterostomum acuticaudatum (adults).

Small strongyles

Adult and immature (fourth stage larvae) small strongyles or cyathostomes, including benzimidazole-resistant strains: Coronocyclus spp., including C. coronatus, C. labiatus, C. labratus; Cyathostomum spp., including C. catinatum, C. pateratum; Cylicocyclus spp., including C. ashworthi, C. elongatus, C. insigne, C. lepostomum, C. nassatus, C. radiatus; Cylicostephanus spp., including C. asymetricus, C. bidentatus, C. calicatus, C. goldi, C. longibursatus, C. minutus; Cylicodontophorus spp., including C. bicornatus; Gyalocephalus capitatus; Parapoteriostomum spp. including P. euproctus, P. mettami; Petrovinema spp. including P. poculatum; Poteriostomum spp. including P. imparidentatum.

Lungworms (adults and immatures)

Dictyocaulus arnfieldi

Pinworms (adults and immatures)

Oxyuris equi

Ascarids (adults and immature)

Parascaris equorum

Hairworms (adults)

Trichostrongylus axei

Large-mouth stomach worms (adults)

Habronema muscae

Neck threadworms (microfilariae)

Onchocerca spp.

Intestinal threadworms (adults)

Strongyloides westeri

Stomach bots

Oral and gastric stages of Gastrophilus spp.

Dosage and administration

EQVALAN Paste for Horses is given orally at the recommended dose rate of 0.2 mg ivermectin per kg of bodyweight. Each syringe delivers 120 mg ivermectin, sufficient to treat 600 kg of bodyweight.

Parasite control program:

All horses and donkeys should be included in a regular parasite control program, with particular attention being paid to mares, foals and yearlings. Foals should be treated initially at 6 to 8 weeks of age, and routine treatment repeated as appropriate.

EQVALAN Paste for Horses is highly effective against gastro-intestinal, cutaneous and pulmonary nematodes and bots of horses. Regular treatment will reduce the chances of verminous arteritis and colic caused by Strongylus vulgaris. With its broad spectrum, the product is well suited to be the major medication in parasite control programs and is well suited to be the major component in a rotational program.

Dosing instructions:

Each weight marking on the syringe plunger will deliver sufficient paste to treat 100kg bodyweight. Unlock the knurled ring by making ¼ turn and slide the knurled ring up the plunger shaft so that the side nearest the barrel is at the prescribed weight marking. Turn the knurled ring ¼ turn to lock in place. Remove the plastic cap from the tip of the nozzle. Make sure the horse's mouth contains no feed. Insert the syringe into the horse's mouth at the interdental space. Advance the plunger as far as it will go, depositing the medication on the base of the tongue.

Pharmaceutical precautions

Do not store above 25°C.

Protect from light.

Keep out of the reach of children.

Further information

Horses and donkeys of all ages, including young foals, pregnant mares and breeding stallions, have been treated with no adverse effects on their health and fertility.

EQVALAN Paste for Horses has been used in conjunction with other equine health care products and no interactions have been identified.

Mild transitory signs (slowed papillary light response and depression) have been seen at a dose of 1.8 mg/kg (9 times the recommended dose). Other signs seen at higher doses include mydriasis, ataxia, tremors, stupor, coma and death. The less severe signs have been transitory. No antidote has been identified; however, symptomatic therapy may be beneficial.

Equitape Worming Paste

Do not use in horses producing milk for human consumption.Withdrawal period for edible tissue: zero daysThe safety of EQUITAPE has not been studied following administration to mares during gestation and lactation, and as such should only be used in mares during pregnancy and lactation after assessment of the benefit/risk balance by your veterinary surgeon.Wash hands thoroughly after treating animals.Do not eat, drink or smoke during application.Any spillage of the product onto human skin should be removed by washing with soap and water.Read entire package insert before use.For animal treatment only.Keep out of reach of children.Environmental SafetyIn order to limit pasture excretion of the product and its metabolites, horses should remain stabled for 2 days after treatment. Unused product or waste material must be disposed of in accordance with national waste disposal requirements

Presentation

A white paste containing: 90.0mg/g praziquantel Ph.Eur as active substance and 0.2mg/g propyl parahydroxybenzoate (E216) and 1.4mg/g methyl parahydroxybenzoate (E218) as preservatives.

Uses

Praziquantel is a pyrazino-isoquinoline derivative. For the single dose treatment of infections with cestodes (tapeworms) of the species Anoplocephala perfoliata sensitive to praziquantel.

Dosage and administration

For oral administration. One 6.67g syringe contains sufficient paste to treat one 600kg horse at the recommended dose rate (1mg praziquantel per kg bodyweight). Each graduation on the calibrated syringe delivers sufficient paste to treat 50kg bodyweight. Use of a scale or weigh tape is recommended to ensure accurate dosing.

Pharmaceutical precautionsNo special precautions for storage. Further information

As tapeworm infection is unlikely to occur in horses before two months of age, treatment of foals below this age is not considered necessary.

In horses with severe infections, treatment may result in mild, transient colic and loose faeces due to the destruction of the tapeworms.

Parasite resistance to a particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

In the absence of compatibility studies this veterinary product must not be mixed with other medicinal products.

Marketing Authorisation Holders: Bayer plc, Animal Health. Division, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA

Distributed in UK by: Fort Dodge Animal Health Ltd, Flanders Road, Southampton, SO30 4QH

Equest Pramox Worming Gel

Horses must not be slaughtered for human consumption within 64 days of treatment.

Do not administer to young foals less than 6.5 months of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use during pregnancy and lactation in mares.

EQUEST PRAMOX Oral Gel is formulated specifically for use in horses only. Dogs or cats may be adversely affected by the concentration of moxidectin in this product if they are allowed to ingest spilled gel or have access to used syringes.

Do not use the same syringe to treat more than one animal unless horses are running together or in direct contact with each other on the same premises.

This product may cause eye irritation, skin irritation and skin sensitisation.

Avoid direct contact with skin and eyes.

The use of protective gloves is recommended.

Wash hands or any exposed area after use.

Do not smoke, drink or eat while handling the product.

In the event of eye contact flush the eye with copious amounts of clean water and seek medical advice.

In case of accidental ingestion, seek medical help and show the doctor the package insert.

For animal treatment only.

Keep out of the reach and sight of children.

Read entire package insert before use.

Environmental safety

In order to limit the impact of moxidectin on dung fauna, and due to insufficient data regarding environmental risk of praziquantel, horses should not be turned out onto pasture within 3 days of treatment.

EQUEST PRAMOX Oral Gel is toxic to fish and aquatic organisms. Do not contaminate ponds, waterways or ditches with product or used syringes. Dispose of any unused product and empty syringes in accordance with guidance from your local waste regulation authority.

Presentation

A pale yellow to orange/pink gel containing 19.5 mg/g moxidectin and 121.7 mg/g praziquantel as active ingredients and 220.0 mg/g benzyl alcohol and 0.80 mg/g butyl hydroxytoluene as preservatives/antioxidants.

Uses

Moxidectin is a second-generation macrocyclic lactone of the milbemycin family. Praziquantel is a parasiticide widely used in many species for the specific control of tapeworm. For the single dose treatment of mixed cestode and nematode or arthropod infections in horses and ponies; caused by moxidectin and praziquantel sensitive strains of:

Large redworm (large strongyles):

- Strongylus vulgaris (adults)

- Strongylus edentatus (adults)

- Triodontophorus brevicauda (adults)

- Triodontophorus serratus (adults)

- Triodontophorus tenuicollis (adults)

Small redworm (small strongyles/cyathostomin) (adults and intraluminal larval stages):

- Cyathostomum spp.

- Cylicocyclus spp.

- Cylicostephanus spp.

- Cylicodontophorus spp.

- Gyalocephalus spp.

Ascarids:

- Parascaris equorum (adults)

Other roundworm species:

- Oxyuris equi (adults)

- Habronema muscae (adults)

- Strongyloides westeri (adults)

- Trichostrongylus axei (adults)

Bots:

- Gasterophilus intestinalis (L2, L3)

- Gasterophilus nasalis (L2, L3)

Tapeworm:

- Anoplocephala perfoliata

- Anoplocephala magna

- Anoplocephaloides mamillana

The egg reappearance period of small redworm is 90 days.

The product is effective against (developing) intramucosal L4 stages of small redworm. At 8 weeks after treatment, early (hypobiotic/inhibited) EL3 stages of small redworm are eliminated.

The product is effective against benzimidazole resistant strains of cyathostomes.

Dosage and administration

For oral administration. One 11.8g syringe contains sufficient gel to treat a 575kg horse at the recommended dose rate (0.4mg moxidectin per kg bodyweight and 2.5mg praziquantel per kg bodyweight). Each graduation on the calibrated syringe delivers sufficient gel to treat 25kg bodyweight. Use of a scale or weight tape is recommended to ensure accurate dosing. To avoid overdosing, care should be taken to accurately dose foals, especially low bodyweight foals or pony foals.

Dosing guideline

The recommended dosing interval for the control of small redworm is 13 weeks. For optimum control of bots, the product should be administered in the autumn, after the end of the fly season and before spring as the larvae may start to pupate and therefore are less sensitive to treatment.

Veterinary advice should be given on appropriate dosing programmes and stock management to achieve optimum parasite control.

Pharmaceutical precautions

Do not store above 25°C.

Use within 6 months after opening.

Do not use after the expiry date stated on the carton after "EXP".

Further information

Parasite resistance to a particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

The veterinary surgeon should give advice regarding appropriate dosing programmes and stock management to achieve adequate parasite control for both tapeworm and roundworm infestations.

In the case of cestode treatment the dose of praziquantel in the product has been selected at the top end of the dosing range.

Flaccid lower lip, ataxia and swelling of the muzzle could be observed on rare occasions in young animals. These adverse effects are transient and disappear spontaneously. In adults transient adverse reactions may occur at 3 times the recommended dose. The symptoms are depression, inappetence, ataxia, flaccid lower lip in the 8 to 24 hours following treatment. Symptomatic treatment is not generally necessary and recovery is generally complete within 24 to 72 hours.

There is no specific antidote.

In case of very high worm burdens, destruction of the parasites may cause a mild transient colic and loose faeces in the treated horse.

EQUEST PRAMOX Oral Gel is specially formulated to be easily expelled by the syringe plunger. Once in the horse’s mouth, EQUEST PRAMOX Oral Gel liquefies. This facilitates dosing and reduces the risk of rejection.

Equimax Worming Gel

For animal treatment only.

Not to be used in foals under two weeks of age.

Some horses carrying heavy infection of Onchocerca microfilariae have experienced reactions with swelling and itching after treatment. It is assumed to be the result of death of large numbers of microfilariae.

These signs resolve within a few days but symptomatic treatment may be advisable.

Equimax Oral paste for Horses has been formulated specifically for use in horses. Dogs and cats may be adversely affected by the concentration of ivermectin in this product, if they are allowed to ingest spilled paste or have access to used syringes.

As ivermectin is extremely dangerous to fish and aquatic life, treated animals should not have direct access to surface water and ditches during treatment.

Wash hands after use.

Avoid eye contact.

Do not smoke or eat while handling the product.

Withdrawal period:

Horses may be slaughtered for human consumption only after 35 days from the last treatment.

Container disposal:

Any unused product or waste material should be disposed of in accordance with local requirements. Ivermectin is EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate surface water or ditches with the product or used containers.

Presentation

A white homogenous, oral gel containing:

1.87% w/w ivermectin Ph.Eur.

14.03% w/w praziquantel Ph.Eur.

Uses

For the treatment and control of adult and immature gastrointestinal roundworms, lungworms, bots and tapeworms of horses, including:

Large strongyles

Strongylus vulgaris adults and 4th larval (arterial) stages

Strongylus edentatus adults and 4th larval (tissue) stages

Strongylus equinus adults

Triodontophorus spp adults

Small strongyles, adults

Cyathostomum spp.

Cylicocyclus spp.

Cylicodontophorus spp.

Cylicostephanus spp.

Gyalocephalus spp.

Hairworms

Trichostrongylus axei adults

Pinworms

Oxyuris equi adults and immatures

Ascarids

Parascaris equorum adults and immatures

Intestinal threadworms

Strongyloides westeri adults

Large-mouth stomach worms

Habronema muscae adults

Neck threadworms

Onchocerca spp. (microfilariae)

Lungworms

Dictyocaulus arnfieldi adult and immature

Stomach bots

Gasterophilus spp. oral and gastric larval stages

Tapeworms

Anoplocephala perfoliata

Anoplocephala magna

Paranoplocephala mamillana

Dosage and administration

Equimax Oral Paste for Horses is given by mouth at the recommended dose rate of 200 micrograms of ivermectin and 1.5mg of praziquantel per kg of bodyweight as a single dose, corresponding to 1.07g of paste per 100kg bodyweight. The first syringe division delivers sufficient paste to treat 100kg of bodyweight. Each subsequent syringe division delivers sufficient paste to treat 50kg of bodyweight. The syringe delivers sufficient paste to treat 700kg bodyweight at the recommended dose rate.

The horse’s weight should be accurately determined to ensure use of the correct dose of product.

Before administration adjust the syringe to the calculated dosage by setting the ring on the plunger.

Weight Dosage Weight Dosage

Up to 100kg 1.070g paste 401-450kg 4.815g paste

101-150kg 1.605g paste 451-500kg 5.350g paste

151-200kg 2.140g paste 501-550kg 5.885g paste

201-250kg 2.675g paste 551-600kg 6.420g paste

251-300kg 3.210g paste 601-650kg 6.955g paste

301-350kg 3.745g paste 651-700kg 7.49g paste

351-400kg 4.280g paste

The animal’s mouth must be free of food. The syringe should be placed between the front and back teeth and the paste deposited at the base of the tongue. Immediately elevate the head for a few seconds to ensure that the product is swallowed. Treatment is recommended at least twice a year, in spring and autumn or according to veterinary advice. Intermediate roundworm treatment is advisable.

Pharmaceutical precautions

Keep out of the reach of children. Store below 30° C. Part-used syringes should be stored below 25° C.

Following withdrawal of the first dose, use the product within 6 months.

Further information

No known interaction with other equine medicaments.

Studies in other species showed no teratogenic or embryotoxic effect from either ivermectin or praziquantel at the recommended doses during therapy.

A tolerance study performed in foals from 2 weeks of age with doses up to 5 times the recommended dosage showed no adverse reactions.

Safety studies conducted with Equimax administered to mares at 3 times the recommended dosage at 14 day intervals during the whole gestation and lactation did not show any abortions, any adverse effects on the gestation, parturition and on the mares general health, nor any abnormalities on the foals.

Safety studies conducted with Equimax administered to stallions at 3 times the recommended dosage did not show any adverse effects in particular on the reproductive performances.

Equimax Worming Tablets

For animal treatment only.

Do not use in foals under 2 weeks of age.

Do not use in mares from which milk is taken for human consumption.

Do not use in horses known to be hypersensitive to the active ingredients or any of the other ingredients.

Special warnings for target species:

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

-too frequent and repeated use of anthelmintics from the same class over an extended period of time,

-underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

Resistance to ivermectin has been reported in Parascaris equorum in horses in a number of countries including ones in the EU. Therefore the use of this product should be based on national (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

The product can be used safely in stallions.

Can be used during pregnancy and lactation.

Special precautions for use in animals:

Avermectins may not be well tolerated in all non target species. Cases of intolerance are reported in dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also in turtles and tortoises.

Dogs and cats should not be allowed to ingest spilled tablets or have access to used packaging due to the potential for adverse effects related to ivermectin toxicity.

Operator Warnings:

Wash hands after use. Avoid contact with the eyes. In case of eye irritation, seek medical attention. Do not eat, drink or smoke while handling this product. Keep out of the reach of children. In the event of accidental ingestion, seek medical advice and show the leaflet to the physician so that he knows what you have taken.

Adverse reactions:

Colic, diarrhoea and anorexia have been reported in very rare occasions post treatment, in particular when there is heavy worm burden. In very rare occasions, allergic reactions such as hypersalivation, lingual oedema and urticaria, tachycardia, congested mucus membranes, and subcutaneous oedema have been reported following treatment with the product.

Withdrawal Period:

Horses may be slaughtered for human consumption only after 35 days from the last treatment.

Container Disposal:

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with national requirements. EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate surface waters or ditches with the product or used container.

Presentation

White, circular, biconcave tablet with brown spots.

Each chewable tablet of 3300 mg contains:

Ivermectin 20mg

Praziquantel 150mg

Uses

For the treatment of mixed cestode, nematode and arthropod infestations, due to adult and immature roundworms, lungworms, bots and tapeworms in horses:

Nematodes

Large-strongyles

Strongylus vulgaris (adult and arterial larvae)

Strongylus edentatus (adult and L4 tissue larval stages)

Strongylus equinus (adult and L4 larval stage)

Triodontophorus spp. (adult)

Small-strongyles

Cyathostomum (adult and non-encysted mucosal larvae): Cylicocyclus spp., Cylicostephanus spp., Gyalocephalus spp.

Ascarids

Parascaris equorum (adult and larvae).

Pinworms

Oxyuris equi (adult and larvae).

Hairworms

Trichostrongylus axei (adult)

Cestodes ( Tapeworm):

Anoplocephala perfoliata,Anoplocephala magna, Paranoplocephala mamillana

As tapeworm infestation is unlikely to occur in horses before two months of age, treatment of foals below this age is not considered necessary.

Stomach Bots

Gasterophilus spp. (larvae).

Dosage and administration

Single oral administration.

200 µg of ivermectin and 1.5 mg of praziquantel per kg of bodyweight corresponding to 1 tablet per 100 kg bodyweight.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Weight Doseage

up to 100 kg 1 tablet

101 - 200 kg 2 tablets

201 - 300 kg 3 tablets

301 - 400 kg 4 tablets

401 - 500 kg 5 tablets

501 - 600 kg 6 tablets

601 - 700 kg 7 tablets

701 - 800 kg 8 tablets

Once the correct dose has been determined, it should be administered in the following way :

Present the tablet in the palm of your hand. Repeat this gesture until the complete dose has been administered. During the initial administration, the tablet can be combined with a small amount of food or a treat to increase the acceptance by the horse.

In the event that the required dose is not ingested an alternative treatment should be administered. Seek the advice of your veterinary practitioner.

Advice regarding appropriate dosing programmes and stock management should be sought to achieve adequate parasite control for both tapeworm and roundworm infestations.

Pharmaceutical precautions

Keep out of reach and sight of children. Do not store above 30°C

Shelf life of the veterinary medicinal product as packaged for sale : 18 months

Shelf life after first opening the immediate packaging : 12 months

Further information

No known interaction with other equine medicaments.

A tolerance study performed in foals with doses up to 5 times the recommended dosage did not show any adverse reactions.

Safety studies conducted with a similar veterinary medicinal product (EQUIMAX oral gel) administered to mares at 3 times the recommended dosage at 14-day intervals during the whole gestation and lactation periods did not result in any abortions, nor any adverse effects during gestation, at parturition or on the mares general health, nor any abnormalities in the foals.

Safety studies conducted with a similar veterinary medicinal product (EQUIMAX® oral gel) administered to stallions at 3 times the recommended dosage did not show any adverse effects in particular on the reproductive performances.

Strongid P Worming Paste

Not for use in horses with known hypersensitivity to the active ingredient.

Only for direct oral administration.

The same oral dose should only be used to dose two animals if they are both healthy and are either running together, or are on the same premises and in direct contact with each other.

Avoid contact with the skin. Wash hands and any other parts of the body which come into contact with the product.

To be used for animal treatment only.

Keep out of the reach of children.

Withdrawal period:

Horse meat: zero days.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

•Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

•Underdosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintics belonging to another pharmacological class and having a different mode of action should be used.

Resistance to pyrantel has been reported in cyathostomes in horses in a number of countries, including the EU. Therefore the use of this product should be based on a local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

Uses

Strongid-P Paste is a safe, effective, well accepted and easily administered broad-spectrum anthelmintic, which is indicated for use in the horse and donkey for the control and treatment of adult infections of large and small strongyles, Oxyuris, Parascaris and Anoplocephala perfoliata.

Strongid-P Paste is effective against benzimidazole resistant strains of small strongyles and should be used wherever the presence of such strains is suspected.

Dosage and administration

Administration

Strongid-P Paste is recommended for direct oral administration in horses, ponies and foals of over four weeks of age and donkeys. It is not necessary to withhold any feed prior to administration. The following method of administration is recommended:

1.Position the locking ring over the appropriate mark on the plunger.

2.Remove the cap from the nozzle.

3.The paste is best deposited on the upper surface (dorsum) of the tongue. Introduce the nozzle end of the syringe at the corner of the mouth (labial commissure). Direct the syringe backwards and depress the plunger to deposit the paste onto the tongue. Providing the paste is given in this way it is unlikely that any rejection will occur. Raising of the horse's head by a hand under the chin sometimes assists in the swallowing process.

Dosage

For the control and treatment of strongyles including benzimidazole resistant strains (redworm), Oxyuris (seatworm/pinworm) and Parascaris (roundworm).

Strongid-P should be used at a dose rate of 19 mg pyrantel embonate per kg bodyweight.

Bodyweight range

NB: 1 kg = 2.2 Ib Dose–contents of

Up to 150 kg ¼ oral doser marked

150 kg

151 kg to 300 kg ½ oral doser marked

300 kg

301 kg to 450 kg ¾ oral doser marked

450 kg

451 kg to 600 kg Full oral doser

marked 600 kg

Note

Position locking ring over appropriate mark on plunger.

Dosing programmes

Strongyles (including benzimidazole resistant strains), Oxyuris and Parascaris.

Foals - one to eight months of age:

Dose every four weeks.

Horses and donkeys over eight months of age:

Routinely dose every six to eight weeks, but during the summer and autumn when at grass dose every four to six weeks.

Always dose three to four days before turning out after in-wintering.

Suckler mares:

It has been shown that reduction of strongyle challenge to the suckling foal at pasture can be achieved by using clean pasture (re-seeded or not grazed the previous year by horses), dosing the mare three to four days before turning out and then at intervals of two to four weeks until the end of autumn.

Ideally mares with foals should go out to `clean' pasture or, if this is not possible, delay turning them out until June.

Dosage

For the control and treatment of Anoplocephala perfoliata: (tapeworm). Strongid-P should be used at a dose rate of 38mg pyrantel embonate per kg bodyweight, that is twice the dose rate for strongyles.

Dosing programme – Anoplocephala perfoliata

The need for retreatment may vary, but if considered necessary should be carried out after an interval of six weeks.

Pharmaceutical precautions

Do not store above 25°C. Store in tightly closed original container.

Protect from direct sunlight.

Any product remaining 2 months after first use of an oral doser should be discarded.

Further information

Strongid-P Paste is well tolerated and is safe to give to horses and donkeys, including young foals of over four weeks of age and pregnant mares and stallions, provided the recommendations are followed.

Pyrantel embonate is the recognised UK name for the active principle in Strongid-P Paste and is synonymous with pyrantel palmoate.

Pyrantel embonate is also available as Strongid-P Granules which is recommended for feed, or stomach-tube administration.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

Strongid P Granules

Not for use in horses with known hypersensitivity to the active ingredient.

Stomach-tube administration: normal precautions should be observed. Only to be carried out by a veterinary surgeon.

Operator warning:

Avoid contact with skin. Wash hands and any other parts of the body which come into contact with the product.

Avoid inhalation of the product. Where a number of horses are to be dosed, for example in a yard, it is recommended to wear a dust mask.

For animal treatment only.

Keep out of reach of children.

Withdrawal period:

Horse meat: zero days.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

•Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

•Underdosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintics belonging to another pharmacological class and having a different mode of action should be used.

Resistance to pyrantel has been reported in cyathostomes in horses in a number of countries, including the EU. Therefore the use of this product should be based on a local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

Presentation

Strongid-P Granules is a pale yellow to buff, free flowing granular material containing 76.736% w/w pyrantel embonate in an inert carrier. Pyrantel embonate is a pale yellow to buff, odourless, non-staining amorphous powder containing 34.6% base activity.

Uses

Strongid-P Granules is a broad-spectrum anthelmintic and is indicated for use in the horse and donkey for the control and treatment of adult infections of large and small strongyles, Oxyuris, Parascaris and Anoplocephala perfoliata.

Strongid-P Granules is effective against benzimidazole resistant strains of small strongyles and should be used wherever the presence of such strains is suspected.

Dosage and administration

To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked.

Administration

Strongid-P Granules is recommended for feed or stomach-tube administration in horses, ponies and foals of over four weeks of age and donkeys. It is not necessary to withhold any feed prior to administration. Administer medicated feed or suspension immediately after mixing.

Feed

Strongid-P Granules should be dispersed evenly in the feed – preferably a relatively reduced quantity to ensure consumption. Any unconsumed medicated feed should be discarded.

Stomach tube

Strongid-P Granules suspends in warm water and it may be administered by a veterinary surgeon via a stomach tube. Add the required amount of Strongid-P Granules to warm water and stir immediately before use. Any medicated water which is not administered within 24 hours should be discarded.

Dosage

For the control and treatment of strongyles including benzimidazole resistant strains (redworm), Oxyuris (seatworm/pinworm) and Parascaris (roundworm), Strongid-P should be used at a dose rate of 19 mg pyrantel embonate per kg bodyweight.

Sachet pack

1 sachet per 300 kg (660 lb) bodyweight. Each sachet contains 7.43 g Strongid-P Granules (5.7 g pyrantel embonate).

Dosing programmes

Strongyles (including benzimidazole resistant strains), Oxyuris and Parascaris.

Foals one to eight months of age:

Dose every four weeks.

Horses and donkeys over eight months of age:

Routinely dose every six to eight weeks, but during the summer and autumn when at grass dose every four to six weeks.

Always dose three to four days before turning out after in-wintering.

Suckler mares:

It has been shown that reduction of strongyle challenge to the suckling foal at pasture can be achieved by using clean pasture (re-seeded or not grazed the previous year by horses), dosing the mare three to four days before turning out and then at intervals of two to four weeks until the end of autumn.

Ideally mares with foals should go out to "clean" pasture or, if this is not possible, delay turning them out until June.

Dosage

For the control and treatment of Anoplocephala perfoliata Tapeworm:

Strongid-P should be used at a dose rate of 38 mg pyrantel embonate per kg bodyweight, that is twice the dose rate for strongyles.

Sachet pack

1 sachet per 150 kg (330 lb) bodyweight. Each sachet contains 7.43 g Strongid-P Granules (5.7 g pyrantel embonate).

Dosing programme – Anoplocephala perfoliata

The need for retreatment may vary, but if considered necessary should be carried out after an interval of six weeks.

Pharmaceutical precautions

Do not store above 25°C.

Protect from sunlight.

If only part of a sachet of granules has been used, fold the opened edge and store in a cool dry place. Part used sachets should be stored below 25°C and used within two months.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

Further information

Strongid-P Granules are well tolerated in horses and donkeys, including young foals of over four weeks of age, pregnant mares, and stallions, provided the recommendations are followed.

Pyrantel embonate is the recognised UK name for the active principle in Strongid-P Granules and is synonymous with pyrantel pamoate.

Pyrantel embonate is also available as Strongid-P Paste and Strongid Caramel, presented in a disposable plastic syringe for direct oral administration.

Panacur Worming Paste

Do not use in horses intended for human consumption.

Operator warnings:

Direct contact with the skin should be kept to a minimum.

Wear impermeable rubber gloves while administering the product.

Wash hands after use.

Environmental warnings:

Dispose of any unused product and empty syringes in accordance with guidance from your local waste regulation authority.

For animal treatment only.

Keep out of reach of children.

Presentation

Syringes containing 24g of an 18.75% paste formulation of fenbendazole and 0.2% apple and cinnamon flavour as a ready to administer oral anthelmintic for horses. 1g Panacur Equine Paste contains 0.187g active ingredient Fenbendazole PhEur.

Uses

A broad spectrum anthelmintic for the treatment and control of adult and immature roundworms of the gastro-intestinal tract in horses and other equines. Panacur also has an ovicidal effect on nematode eggs.

Panacur effectively treats and controls the following roundworm infections:

Large strongyles (adults and migrating larval stages of S. vulgaris; adults and tissue larval stages of S. edentatus).

Benzimidazole susceptible adult and immature small strongyles (Cyathostomes) including encysted mucosal 3rd and 4th stage larvae; it is also effective against encysted inhibited 3rd stage larvae in the mucosa.

Adult and immature Oxyuris spp., Strongyloides spp., and Parascaris equorum.

Dosage and administration

No dietary control is required before or after treatment.

Routine treatment

Administer orally, 1 syringe per 600 kg bodyweight (= 7.5 mg fenbendazole/kg bodyweight).

Practical dosage recommendations:

Weight Type Routine treatment

Up to 100kg Miniature ponies Syringe mark 100kg

101-300kg Donkey, Shetland and other small

ponies, foals Syringe mark 300kg

301-400kg Dartmoor, New Forest, Welsh etc Syringe mark 400kg

401-500kg Light hunter, Arabs etc. Syringe mark 500kg

501-600kg Thoroughbreds 1 syringe

601kg and over Heavy hunters, draught horses 1 syringe +

additional 100kg

syringe marks for each extra 100kg bodyweight

Increased dosing for specific infections:

Five day course

For the treatment and control of migrating and tissue larval stages of large strongyles, encysted mucosal 3rd and 4th stage small strongyle larvae and encysted inhibited 3rd stage small strongyle larvae in the mucosa, administer 1 syringe per 600kg bodyweight daily for 5 days (=7.5mg fenbendazole/kg bodyweight daily for 5 days).

Single dose treatments

For the treatment and control of encysted mucosal stages of small strongyles administer 1 syringe per 150kg bodyweight (=30 mg fenbendazole/kg bodyweight).

For the treatment and control of migrating larval and tissue stages of large strongyles administer 1 syringe per 75kg bodyweight (=60 mg fenbendazole/kg bodyweight).

For the treatment and control of Strongyloides westeri in suckling foals administer 1 syringe per 90kg bodyweight (=50 mg fenbendazole/kg bodyweight).

Panacur Equine Paste should be administered orally by squeezing the paste from the syringe onto the back of the horse's tongue.

Assess bodyweight as accurately as possible before calculating the dosage. The use of a `weigh-band' is recommended.

Pregnant mares and young foals can be safely treated with Panacur Equine Paste (fenbendazole) at recommended dosage levels.

Recommended dosing programmes:

All horses should be routinely treated with the single dose of Panacur Equine Paste every 6–8 weeks.

Treatment of encysted inhibited and encysted mucosal dwelling larvae should ideally be performed in the autumn (ideally late October/November) and again in the spring (ideally in February). However, for horses that fail to maintain condition or bought-in horses with unknown worming history, the treatment should be given at any time of year.

Pharmaceutical precautions

Do not store above 25°C. Protect from direct sunlight.

Further information

Studies have indicated that inhibited 3rd stage small strongyle larvae represent 50% of the total larval population in the horse.

Panacur has been used extensively for the treatment of worm infestations in exotic animal species. For further information on suggested dose rates, please contact the Veterinary Adviser of the company.

Panacur Worming Granules

Do not use in horses intended for human consumption.

Operator warnings:

Direct contact with the skin should be kept to a minimum. Wash hands after use.

Environmental warnings:

Dispose of any unused product and empty sachets in accordance with guidance from your local waste regulation authority.

For animal treatment only.

Keep out of reach of children.

Assess bodyweight as accurately as possible before calculating the dosage.

Presentation

A 22% granulate formulation of Fenbendazole as a ready to administer oral anthelmintic for horses. 1 g Panacur Equine Granules contains 0.22 g active ingredient Fenbendazole, PhEur.

Uses

A broad-spectrum anthelmintic for the treatment and control of adult and immature roundworms of the gastro-intestinal tract in horses and other equines. Panacur also has an ovicidal effect on nematode eggs.

Horses

Panacur effectively treats and controls the following roundworm infections:

-Large strongyles (adults and migrating larval stages of S. vulgaris; adults and tissue larval stages of S. edentatus).

-Adult and immature small strongyles (Cyathostomes) (benzimidazole susceptible) including encysted mucosal 3rd and 4th stage larvae; it is also effective against inhibited 3rd stage larvae (encysted) in the mucosa.

-Adult and immature Oxyuris spp., Strongyloides spp. and Parascaris equorum.

Dosage and administration

Horses: For routine treatment of horses administer orally 5 g Panacur Equine Granules per 150 kg bodyweight.

(= 7.5 mg fenbendazole/kg bodyweight)

Practical dosage recommendations:

Up to 150 kg 5 g

151 to 300 kg 10 g

301 to 450 kg 15 g

451 to 600 kg 20 g

601 to 750 kg 25 g

751 to 900 kg 30 g

Panacur Equine Granules sachet packs each contain 10.2 g of granules and can be used as follows:

Practical dosage recommendations:

Foals and ponies up to 300 kg

bodyweight 1 sachet

Thoroughbreds and other breeds of

horses up to 600 kg bodyweight 2 sachets

Heavy hunters, heavy draught horses 3 sachets

Donkeys 1 sachet

Increased dosing for specific infections:

Five day course

For the treatment and control of migrating larval and tissue stages of large strongyles, encysted mucosal 3rd and 4th stage larvae and inhibited 3rd stage larvae (encysted) in the mucosa, administer 5g Panacur Equine Granules per 150kg bodyweight daily for 5 days.

(=7.5mg fenbendazole/kg bodyweight daily for 5 days)

Single dose treatments

For the treatment and control of encysted mucosal stages of small strongyles, administer 20g Panacur Equine Granules per 150kg bodyweight (=30mg fenbendazole /kg bodyweight).

For the treatment and control of migrating larval and tissue stages of large strongyles, administer 40g Panacur Equine Granules per 150 kg bodyweight (=60mg fenbendazole /kg bodyweight).

Diarrhoea caused by Strongyloides westeri in two to three week old suckling foals should be treated with Panacur 10% suspension at a dose rate of 25ml per 50kg bodyweight (=50mg fenbendazole /kg bodyweight).

Panacur Equine Granules should be sprinkled onto concentrate or grain feed and the full dosage given as one administration.

Assess bodyweight as accurately as possible before calculating the dosage. The use of a `weigh band' is recommended.

Pregnant mares and young foals may be safely treated with fenbendazole at therapeutic dosage levels.

Recommended dosing programme:

All horses should be routinely wormed with the single dose of Panacur Equine Granules every 6-8 weeks.

Treatment of encysted mucosal dwelling larvae should ideally be done in the autumn (late October/November) and again in the Spring. However, for horses that fail to maintain condition or bought-in horses with unknown worming history, the treatment can be given at any time of the year.

Pharmaceutical precautions

None.

Further information

Panacur granules are odourless and tasteless and are readily consumed by animals.

Panacur has been extensively used for the treatment of worm infestations in exotic animal species. For further information on suggested dose rates, please contact the Veterinary Adviser of the company.

Studies have indicated that inhibited 3rd stage small strongyle larvae represent 50% of the total larval population in the horse.

Panacur Equine Guard

Do not use in horses intended for human consumption.

Operator warnings:

Direct contact with the skin should be kept to a minimum.

Wear suitable protective clothing including impermeable rubber gloves.

Wash hands after use.

Environmental warnings:

Dangerous to fish and aquatic life. Do not contaminate ponds, waterways or ditches with the product or used containers.

Dispose of empty packaging and any remaining product in the household refuse.

Intensive use or misuse of anthelmintics can give rise to resistance. To reduce this risk, dosing programmes should be discussed with your veterinary surgeon.

For animal treatment only.

Keep out of the reach and sight of children.

Presentation

A 10% suspension of Fenbendazole as a ready to administer oral anthelmintic for horses. 1 ml Panacur Equine Guard contains 100 mg active ingredient Fenbendazole.

Uses

For the treatment and control of adult and immature roundworms of the gastro-intestinal tract in horses and other equines. The product is effective for the treatment and control of encysted mucosal 3rd and 4th stage small strongyle larvae and is also effective against encysted inhibited 3rd stage small strongyle larvae in the mucosa.

The product is also effective in controlling other immature and mature roundworms including large redworm (Strongylus edentatus and Strongylus vulgaris) and migrating large redworm, Ascarids (Parascaris equorum), Oxyuris and Strongyloides species and benzimidazole-susceptible adult and immature small strongyles.

Panacur Equine Guard also has an ovicidal effect on nematode eggs.

Dosage and administration

No dietary control is required before or after treatment.

For the treatment and control of migrating and tissue larval stages of large strongyles, encysted mucosal 3rd and 4th stage small strongyle larvae and encysted inhibited 3rd stage small strongyle larvae in the mucosa administer 5ml of the product per 65kg bodyweight daily for 5 days (= 7.5mg fenbendazole/kg bodyweight daily for 5 days).

This product can be easily administered by mixing with grain or concentrate feed. The full daily dosage must be given as one administration.

Pregnant mares and foals may also be safely treated with fenbendazole at therapeutic dosage levels.

Assess bodyweight as accurately as possible before calculating the dosage. The use of a ‘weigh band’ is recommended.

Recommended dosing programme:

Treatment of encysted inhibited and encysted mucosal dwelling larvae should be performed in the autumn (ideally late October/November) and again in the Spring (ideally in February). However, for horses that fail to maintain condition or bought-in horses with unknown worming history, the treatment can be given at any time of the year.

Treatment with this product should form part of an integrated worming plan. Consult with your supplier for advice regarding wormers to use throughout the year.

Pharmaceutical precautions

Protect from freezing. Shake container before use.

Mix the medicated feed thoroughly prior to administration, for example by rolling the drum or barrel.

Liquid feed containing the product will remain stable for up to 3 months.

Further information

Panacur has been extensively used for the treatment of worm infestations in exotic animal species. For further information on suggested dose rates, please contact the veterinary adviser of the Company.

Fenbendazole belongs to the benzimidazole (1—BZ) class of anthelmintics.

Studies have indicated that inhibited 3rd stage small strongyle larvae represent 50% of the total larval population in the horse.

All Equi-store prices of horse wormers and pet wormers include vat and FREE UK Delivery.

  • Equi-store
  • Dobbies Garden Centre
  • Boclair Rd
  • Milngavie
  • Glasgow
  • G62 6EP

© 2011 Equi-store